Education
About Us
Working with TipRanks
Follow Us
Intellia Therapeutics (NTLA)
NASDAQ:NTLA
Top Page
Intellia Therapeutics
(NASDAQ:NTLA)39Underperform
Positive Factors
Financial Outlook
Ongoing restructuring, including a 27% workforce reduction, is expected to extend the operational runway into the first half of 2027.
Pipeline Development
NTLA-2002 is poised to be the historic first in vivo genome editing therapeutic to launch for HAE.
Negative Factors
Competition
Competition in the ATTR-CM space is increasing due to aggressive development plans from competitors like Alnylam.
Intellia Therapeutics (NTLA) vs. S&P 500 (SPY)
Market Cap
$941.49M
Dividend YieldN/A
Average Volume (3M)3.35M
Price to Earnings (P/E)―
Beta (1Y)2.97
Revenue Growth59.55%
EPS Growth3.09%
CountryUS
Employees526
SectorHealthcare
Sector Strength74
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.25
Shares Outstanding103,517,460
10 Day Avg. Volume4,195,759
30 Day Avg. Volume3,349,833
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.90
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$36.61Price Target Upside302.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering20
Intellia Therapeutics Business Overview & Revenue Model
Company DescriptionIntellia Therapeutics (NTLA) is a leading biotechnology company specializing in the development and commercialization of CRISPR/Cas9-based gene editing therapies. The company operates in the biotech sector with a focus on creating treatments that can potentially cure a wide range of genetic diseases by precisely editing disease-causing genes. Intellia's core products are its gene-editing platforms and therapies, which are in various stages of clinical development, targeting conditions such as transthyretin amyloidosis and hereditary angioedema.
How the Company Makes MoneyIntellia Therapeutics makes money primarily through strategic collaborations, partnerships, and licensing agreements with other pharmaceutical and biotech companies. These partnerships often provide milestone payments and royalties based on the successful development and commercialization of therapies using Intellia's proprietary CRISPR/Cas9 technology. Additionally, Intellia may generate revenue from government grants and research funding to support their innovative projects. As their therapies progress through clinical trials and potentially reach the market, product sales will become a significant revenue stream for the company.
Intellia Therapeutics Financial Statement Overview
Summary
Intellia Therapeutics is in a typical growth and development phase for a biotech company, characterized by high R&D expenses leading to net losses and negative cash flows. While the company maintains a strong cash position, its revenue has dwindled, and its balance sheet reflects declining shareholder equity. The financials suggest the firm is investing heavily in its pipeline but faces significant risks related to its future revenue generation and profitability.Income Statement
Intellia Therapeutics has faced a challenging financial environment, with declining revenues from $57.99 million in 2020 to $36.27 million in 2023, and ultimately to zero in 2024. The company has consistently incurred net losses, with a significant net loss of $519.02 million in 2024, indicating high operational costs and low revenue, characteristic of a biotech firm in early stages of development.15
Very Negative
Balance Sheet
The balance sheet shows adequate cash reserves with $601.52 million in cash and equivalents. However, the debt-to-equity ratio stands at 0.24, indicating manageable leverage, but the persistent decrease in stockholders' equity from $1.05 billion in 2023 to $871.96 million in 2024 suggests a deterioration in shareholder value. The equity ratio is relatively stable, providing a moderate level of financial stability.40
Negative
Cash Flow
The cash flow statement highlights negative free cash flow each year, with a free cash flow of -$408.07 million in 2024, driven by high operating cash outflows. The operating cash flow to net income ratio is unfavorable due to consistent losses, signaling inefficiencies in cash generation relative to expenses. This is typical for a biotech firm still in development phases.25
Negative
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 57.88M | 36.27M | 52.12M | 33.05M | 57.99M | Gross Profit |
| 57.88M | 27.30M | 44.55M | 26.16M | -92.41M | EBIT |
| -534.26M | -515.29M | -458.16M | -267.85M | -136.58M | EBITDA |
| -523.98M | -506.31M | -450.59M | -260.96M | -130.27M | Net Income Common Stockholders |
| -519.02M | -481.19M | -490.21M | -259.72M | -125.57M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 601.51M | 912.22M | 1.26B | 1.09B | 597.37M | Total Assets |
| 1.19B | 1.30B | 1.52B | 1.29B | 676.32M | Total Debt |
| 210.20M | 115.35M | 130.70M | 74.02M | 39.30M | Net Debt |
| 21.02M | -111.40M | -392.80M | -49.38M | -120.72M | Total Liabilities |
| 319.06M | 250.81M | 284.53M | 254.22M | 149.25M | Stockholders Equity |
| 871.96M | 1.05B | 1.24B | 1.04B | 527.07M |
| Cash Flow | Free Cash Flow | |||
| -408.07M | -408.07M | -391.68M | -237.79M | -53.50M | Operating Cash Flow |
| -394.09M | -394.09M | -333.29M | -225.03M | -49.91M | Investing Cash Flow |
| -31.35M | -31.35M | 160.31M | -550.78M | -214.49M | Financing Cash Flow |
| 185.75M | 130.32M | 582.96M | 736.69M | 371.78M |
Intellia Therapeutics Technical Analysis
Negative
9.10
Price Trends
10.83
Negative
13.42
Negative
18.29
Negative
Market Momentum
-0.22
Positive
36.69
Neutral
12.31
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NTLA, the sentiment is Negative. The current price of 9.1 is below the 20-day moving average (MA) of 10.47, below the 50-day MA of 10.83, and below the 200-day MA of 18.29, indicating a bearish trend. The MACD of -0.22 indicates Positive momentum. The RSI at 36.69 is Neutral, neither overbought nor oversold. The STOCH value of 12.31 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NTLA.
Intellia Therapeutics Risk Analysis
Intellia Therapeutics disclosed 66 risk factors in its most recent earnings report. Intellia Therapeutics reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Intellia Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
50 Neutral | $146.11M | ― | -119.89% | ― | 150.95% | 5.48% | |
49 Neutral | $7.05B | 0.34 | -55.09% | 2.46% | 25.27% | -3.43% | |
49 Neutral | $3.73B | ― | -18.96% | ― | -89.95% | -123.71% | |
48 Neutral | $454.80M | ― | -22.72% | ― | -50.30% | -159.03% | |
45 Neutral | $2.21B | ― | -51.36% | ― | -83.18% | -144.95% | |
39 Underperform | $941.49M | ― | -59.52% | ― | 59.55% | 3.09% | |
38 Underperform | $562.08M | ― | -40.27% | ― | 174.98% | 25.06% |
* Healthcare Sector Average
Performance Comparison
NTLA
Intellia Therapeutics
9.10
-21.15
-69.92%
ARCT
Arcturus Therapeutics
15.49
-22.07
-58.76%
EDIT
Editas Medicine
1.76
-7.38
-80.74%
CRSP
Crispr Therapeutics AG
43.45
-37.54
-46.35%
BEAM
Beam Therapeutics
26.44
-12.07
-31.34%
VERV
Verve Therapeutics
6.12
-9.02
-59.58%
Intellia Therapeutics Earnings Call Summary
Earnings Call Date: Feb 27, 2025 | % Change Since: -15.74% | Next Earnings Date: May 1, 2025
Earnings Call Sentiment Neutral
Intellia Therapeutics reported strong progress in its clinical pipeline, particularly with Phase III enrollment for HAE and ATTR amyloidosis, and demonstrated a solid financial position to support ongoing operations. However, the company faced increased operating expenses and restructuring challenges, including program discontinuation and workforce reductions.Highlights
Strong Enrollment in Phase III Trials
Enrollment in Phase III studies for hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR) is progressing well, with expectations to exceed 550 patients by year-end in the MAGNITUDE trial.
Positive Data from Phase I Trials
Phase I data for NTLA-2001 showed a mean serum TTR reduction of 90% at 12 months, indicating potential disease stabilization or improvement for ATTR amyloidosis patients.
Robust Financial Position
Intellia reported approximately $861.7 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing a solid financial foundation to fund operations into 2027.
Regenerative Medicine Advanced Therapy Designation
Nex-z received FDA's RMAT designation for ATTR amyloidosis, facilitating close collaboration with the FDA towards a BLA filing by 2028.
Lowlights
Increased Operating Expenses
R&D expenses increased by $7.9 million year-over-year, primarily due to the advancement of lead programs.
Discontinuation of NTLA-3001
Intellia discontinued NTLA-3001 in favor of a second-generation approach, leading to program wind-down costs.
Workforce Reduction and Restructuring Costs
Intellia announced restructuring efforts, including a workforce reduction, incurring approximately $8 million in severance costs.
Company Guidance
During Intellia Therapeutics' fourth quarter and full-year 2024 financial results call, the company provided key guidance metrics for its clinical programs and financial outlook. They announced the completion of enrollment for the NTLA-2002 Phase III study for hereditary angioedema (HAELO) in the second half of 2025 and anticipated a BLA filing in 2026. Similarly, for the transthyretin amyloidosis (ATTR) MAGNITUDE study, they expect to exceed 550 patients by the end of 2024, targeting a second BLA filing by 2028. The company's cash position was reported at $861.7 million as of December 31, 2024, down from $1 billion the previous year. They revealed an increase in R&D expenses to $116.9 million for Q4 2024, primarily driven by lead program advancements, and a projected 5% to 10% decline in GAAP operating expenses due to a restructuring plan. Intellia also highlighted a significant increase in collaboration revenue to $12.9 million from negative $1.9 million year-over-year, attributed mainly to the Regeneron license and collaboration agreement.Intellia Therapeutics Corporate Events
Executive/Board ChangesBusiness Operations and Strategy
Intellia Therapeutics Restructures to Focus on Late-Stage Programs
Neutral
Jan 10, 2025
Intellia Therapeutics announced a strategic restructuring to focus on its late-stage programs, NTLA-2002 for HAE and nexiguran ziclumeran for ATTR amyloidosis, which includes a 27% reduction in workforce and is expected to extend the company’s cash reserves into 2027. As part of this restructuring, Laura Sepp-Lorenzino, the Chief Scientific Officer, will retire by the end of 2025, with Birgit Schultes stepping in as her successor. The company aims to advance its clinical and commercial readiness by 2026, with pivotal studies and commercialization efforts underway to address significant unmet medical needs.
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.